# Redpin Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/redpin-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.redpinrx.com
- Total disclosed funding: $16M
- Latest round: Series A (Mar 25, 2020)
- Investors on record: 5

## About

Redpin Therapeutics, Inc. specializes in developing innovative gene therapies aimed at addressing chronic diseases. The company leverages advanced technology platforms to create solutions with the potential to improve patient outcomes.Founded in 2017 in New York, US, Redpin Therapeutics, Inc. focuses on gene therapy development. The company was recently acquired on November 16, 2022, by a consortium including Patient Square Capital and others, which enhances its strategic capabilities. Elma Hawkins serves as CEO. The company has successfully completed 3 funding deals, with the latest funding round being a Series A that secured USD 15.50 mn, bringing the total amount raised to USD 15.50 mn.Redpin Therapeutics, Inc. offers a range of gene therapies designed to tackle chronic diseases. These therapies aim to provide innovative solutions that enhance the quality of life for patients. The company caters to various healthcare stakeholders, focusing on creating treatments that address unmet medical needs and leverage cutting-edge technology.The company generates revenue primarily through partnerships and collaborations in the biotech sector, emphasizing a Business-to-Business (B2B) structure that promotes sustainable growth. The revenue model is supported by ongoing projects and agreements with healthcare entities, reinforcing its commitment to advancing gene therapy solutions.Redpin Therapeutics, Inc. plans to integrate its platform and pipeline into Kriya's gene therapy engine following its recent acquisition. This strategic move aims to enhance the development of gene therapies that address diseases affecting millions globally. The company is focused on expanding its product offerings and is exploring new markets, particularly in North America and Europe, to broaden its reach. The recent funding will be utilized to accelerate these initiatives, ensuring timely advancements in gene therapy development.

## Funding rounds

- Series A, Mar 25, 2020, $16M — Alexandria Venture Investments, Takeda Ventures, New York Ventures, 4BIO Capital Partners, Arkin Capital
- Seed, Jan 1, 2018 — Alexandria Venture Investments, New York Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed, Series A
- New York Ventures (https://capitalatlas.ai/funds/new-york-ventures) — Seed, Series A
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series A
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series A